A 425619 - CAS 581809-67-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
TRP Channel
A 425619 is a potent and selective TRPV1 antagonist (IC50 = 3-9 nM) that inhibits TRPV1 activation by anandamide and N-arachidonoyl-dopamine. A 425619 exhibits an inhibitory effect against inflammatory, postoperative and osteoarthritic in vivo pain models.
Brife Description:
TRPV1 antagonist
≥98% by HPLC
A-425619; N-5-Isoquinolinyl-N'-[[(4-(trifluoromethyl)phenyl]methyl]urea
Canonical SMILES:
1.Acidification of rat TRPV1 alters the kinetics of capsaicin responses.
Neelands TR;Jarvis MF;Han P;Faltynek CR;Surowy CS Mol Pain. 2005 Sep 28;1:28.
TRPV1 (vanilloid receptor 1) receptors are activated by a variety of ligands such as capsaicin, as well as by acidic conditions and temperatures above 42 degrees C. These activators can enhance the potency of one another, shifting the activation curve for TRPV1 to the left. In this study, for example, we observed an approximately 10-fold shift in the capsaicin EC50 (640 nM to 45 nM) for rat TRPV1 receptors expressed in HEK-293 cells when the pH was lowered from 7.4 to 5.5. To investigate potential causes for this shift in capsaicin potency, the rates of current activation and deactivation of whole-cell currents were measured in individual cells exposed to treatments of pH 5.5, 1 microM capsaicin or in combination. Acidic pH was found to both increase the activation rate and decrease the deactivation rate of capsaicin-activated currents providing a possible mechanism for the enhanced potency of capsaicin under acidic conditions. Utilizing a paired-pulse protocol, acidic pH slowed the capsaicin deactivation rate and was readily reversible. Moreover, the effect could occur under modestly acidic conditions (pH 6.5) that did not directly activate TRPV1. When TRPV1 was maximally activated by capsaicin and acidic pH, the apparent affinity of the novel and selective capsaicin-site competitive TRPV1 antagonist, A-425619, was reduced approximately 35 fold.
2.Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
Joshi SK;Honore P;Hernandez G;Schmidt R;Gomtsyan A;Scanio M;Kort M;Jarvis MF J Pain. 2009 Mar;10(3):306-15. doi: 10.1016/j.jpain.2008.09.007. Epub 2008 Dec 13.
Evidence implicating Nav1.8 and TRPV1 ion channels in various chronic pain states is extensive. In this study, we used isobolographic analysis to examine the in vivo effects of the combination of the Nav1.8 blocker A-803467 [5-(4-Chloro-phenyl)-furan-2-carboxylic acid (3,5-dimethoxy-phenyl)-amide] with 2 structurally distinct TRPV1 antagonists, A-840257 [1-(1H-Indazol-4-yl)-3-([R]-4-piperidin-1-yl-indan-1-yl)-urea] or A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea]. The antinociceptive effects of the Nav1.8 blocker alone and in combination with each TRPV1 antagonist were examined in an inflammatory (complete Freund's adjuvant, CFA) and a neuropathic (spinal nerve ligation, SNL) pain model after systemic (intraperitoneal) administration. Alone, A-803467 was efficacious in both CFA and SNL models with ED(50) values of 70 (54.2 to 95.8) mg/kg and 70 (38.1 to 111.9) mg/kg, respectively. The ED(50) values of the TRPV1 antagonists A-840257 and A-425619 alone in the CFA model were 10 (3.6 to 14.9) mg/kg and 43 (24.1 to 62.2) mg/kg, respectively; both were without significant effect in the SNL model. A series of experiments incorporating 1:1, 3:1, or 0.3:1 ED(50) dose-ratio combinations of A-840257 and A-803467, or A-425619 and A-803467 were performed in both pain models, and the effective doses of mixtures that produced 50% antinociception (ED(50, mix)) were determined by isobolographic analysis.
3.A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
Honore P;Wismer CT;Mikusa J;Zhu CZ;Zhong C;Gauvin DM;Gomtsyan A;El Kouhen R;Lee CH;Marsh K;Sullivan JP;Faltynek CR;Jarvis MF J Pharmacol Exp Ther. 2005 Jul;314(1):410-21. Epub 2005 Apr 18.
The vanilloid receptor 1 (VR1, TRPV1), which is a member of the transient receptor potential (TRP) superfamily, is highly localized on peripheral and central processes of nociceptive afferent fibers. Activation of TRPV1 contributes to the pronociceptive effects of capsaicin, protons, heat, and various endogenous lipid agonists such as anandamide and N-arachidonoyl-dopamine. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)urea] is a novel potent and selective antagonist at both human and rat TRPV1 receptors. In vivo, A-425619 dose dependently reduced capsaicin-induced mechanical hyperalgesia (ED50 = 45 micromol/kg p.o.). A-425619 was also effective in models of inflammatory pain and postoperative pain. A-425619 potently reduced complete Freund's adjuvant-induced chronic inflammatory pain after oral administration (ED50 = 40 micromol/kg p.o.) and was also effective after either i.t. administration or local injection into the inflamed paw. Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p.o. for 5 days. A-425619 also showed partial efficacy in models of neuropathic pain. A-425619 did not alter motor performance at the highest dose tested (300 micromol/kg p.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related TRP Channel Products

CAS 939040-79-6 AMG 21629

AMG 21629
(CAS: 939040-79-6)

AMG 21629 has been found to be an effective and selective TRPV1 antagonist, which could probably be useful in the treatment of pains associated with cancer and ...

(CAS: 878811-00-8)

MK-2295 is a potent TRPV1 antagonist. TRPV1 antagonists has the potential as analgesic and anti-inflammatory agents.

CAS 659730-32-2 AMG-517

(CAS: 659730-32-2)

AMG-517 is a potent and selective TRPV1 antagonist, antagonizes capsaicin, proton, and heat activation of TRPV1 with IC50 of 0.76 nM, 0.62 nM and 1.3 nM.

CAS 1221349-53-6 TC-I 2014

TC-I 2014
(CAS: 1221349-53-6)

TC-I 2014 is a potent TRPM8 antagonist (IC50 = 0.8, 3.0 and 4.4 nM for canine, human and rat channels, respectively) displaying antiallodynic properties in vivo...

(CAS: 956274-94-5)

Mavatrep is an orally bioavailable, potent and selective TRPV1 antagonist with Ki value of 6.5 nM, which exhibits minimal effect on the enzymatic activity of CY...

CAS 349085-38-7 HC-030031

(CAS: 349085-38-7)

HC-030031 is a selective TRPA1 channel blocker that antagonizes AITC- and formalin-evoked calcium influx with IC50 of 6.2 μM and 5.3 μM respectively.

CAS 68489-09-8 WS12

(CAS: 68489-09-8)

WS12 is a potent TRPM8 agonist. It acts as a cooling agent with EC50 value of 193 nM. It robustly activated TRPM8 in low micromolar concentrations, thus display...

CAS 138977-28-3 Capsazepine

(CAS: 138977-28-3)

Capsazepine, a benzazepine derivative, has been found to be a sensory neurone excitotoxin that could be used against hyperalgesic responses. IC50: 562 nM (Rat T...

Chemical Structure

CAS 581809-67-8 A 425619

Quick Inquiry

Verification code

Featured Items